Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
Prakash Gaba of prakashgaba.com is of the view that one may stay invested in Venus Remedies.
 
                                                                                            Gaurang Shah of Geojit Financial Services is of the view that one may prefer Granules India.
 
                                                                                            Price to book value measure is used for those companies whose present value of the assets cannot be truly reflected in the book value. For banks’ valuation, P/BV is most suited given its borrowing business model and narrow RoE structure.
 
                                                                                            SP Tulsian of sptulsian.com, in an interview to CNBC-TV18, gave his views on various stocks.
 
                                                                                            Watch the interview of Vishal Malkan, CMT at malkansview.com and Lancelot D'Cunha, CEO of ITI Wealth Management Pvt Ltd with Reema Tendulkar & Sumaira Abidi on CNBC-TV18, in which they spoke about specific stocks and sectors.
 
                                                                                            Lancelot D'Cunha, CEO at ITI Wealth management is of the view that one may exit Venus Remedies.
 
                                                                                            Manav Chopra of Nirmal Bang recommends buying Biocon for a target price of Rs 520 and Venus Remedies for a target price of Rs 370.
 
                                                                                            Dharmesh Kant, IndiaNivesh Securities Private Limited advises buying Tamil Nadu Newsprint and Papers for a target price of Rs 172 and Pratibha Industries for a target price of Rs 73.
 
                                                                                            Lancelot D Cunha of ITI Wealth Management recommends buying LIC Housing Finance with a target of Rs 172 and advises selling Tech Mahindra August Futures.
 
                                                                                            Shahina Mukadam of Varun Capital recommended buying Tata Global Beverage with a target price of Rs 152 and Jet Airways with a target price of Rs 352.
 
                                                                                            Tata Motors may slip to Rs 225, says Anil Manghnani, Modern Shares & Stock Brokers.
 
                                                                                            Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.
 
                                                                                            Venus Remedies may rally to Rs 225 in a year‘s time, says SP Tulsian, sptulsian.com.